Table 2.
Patient demographic and disease characteristics for independent prospective validation cohort (UK, France, Italy, Netherlands).
| Healthy Controls | RA (adalimumab ADA−) | RA (adalimumab ADA+) | |
|---|---|---|---|
| n | 31 | 12 | 12 |
| Sex, female n (%) | 24 (68) | 8 (67) | 10 (83) |
| Age (years), mean (SD) | 27 (10.7) | 59 (15.7) | 45 (12.6) |
| DAS28 (SD) | – | 2.45 (1.2) | 3.49 (1.2) |
| Seropositive (RF+/CCP+) n (%) | – | 12 (100) | 12 (100) |
| CRP mg/l (SD) | – | 7.5 (11.6) | 9.2 (9.1) |
| LOCATION | |||
| UK | 1 | 1 | |
| France | 6 | 3 | |
| Italy | 1 | 1 | |
| Netherlands | 4 | 7 | |
| CONCOMITANT DMARD TREATMENT | |||
| MTX use, n (%) | 10 (83.3%) | 8 (66.7%) | |
| Average MTX dose, mg/week, mean (SD) | 18.25 (5.3) | 15.63 (6.6) | |
| Prednisolone use, n (%) | 1 (8.3%) | 3 (25%) | |
| Prednisone use, n (%) | 3 (25%) | 3 (25%) | |
| Hydroxychloroquine use, n (%) | 3 (25%) | 0 (0%) | |
| Leflunomide use, n (%) | 0 (0%) | 3 (25%) | |
| Sulfasalazine use, n (%) | 2 (17%) | 0 (0%) | |
CRP and DAS28 are not statistically different; age is statistically different (p = 0.04) between ADA+ and ADA− RA cohorts.
Values in the table represent mean ± standard deviation (SD), or number of patients (n) with proportion of total (%) where indicated.
Month 12 (M12).
All patients received 40 mg adalimumab every other week.